RxDoctor Payments DataLook up a doctor →

William Smith, MD

Internal Medicine · New Orleans, LANPI 1124024054

Payments from drug & device makers

$50,456,531in general payments, 2019–2025

Across 3,154 payments — averaging $15,998 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7.2M
  • Pfizer$7.1M
  • Modernatx, Inc.$6.8M
  • Merck$3.6M
  • Janssen Research & Development, LLC$3.5M
  • Biontech SE$3.5M
  • plus $18.9M from 50 others
$138,331in research payments, 2019–2025

Across 27 payments — averaging $5123.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Valneva Austria GmbH$131K
  • Pfizer$3K
  • Eli Lilly$3K
  • Sanofi Pasteur Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)20$7,150,306
Pfizer315$7,096,478
Modernatx, Inc.596$6,828,378
Merck77$3,551,500
Janssen Research & Development, LLC145$3,524,228
Biontech SE377$3,454,679
Sanofi Pasteur Inc.59$2,083,499
Genentech, Inc.143$1,668,087
Valneva Austria GmbH57$1,631,088
Novartis17$1,430,960
Astrazeneca UK Limited4$1,385,790
Eisai Inc.254$1,321,704
GSK46$947,006
Eli Lilly25$925,422
Boehringer Ingelheim28$917,066
Johnson & Johnson23$900,895
Emergent Biosolutions Inc.218$764,004
Vivus LLC44$704,656
Bristol Myers Squibb25$637,765
Takeda Pharmaceuticals U.S.A., Inc.4$552,764
Sage Therapeutics, LLC2$470,249
Seqirus USA Inc305$417,364
AbbVie(2 entities)29$377,774
Amgen3$373,261
Sanofi US Services Inc.16$174,838
Arthrex28$170,894
Biohaven Pharmaceuticals, Inc.27$132,346
Boehringer Ingelheim International GmbH124$103,457
Roche Products Limited17$88,410
Bayer3$80,683
Sanofi5$75,312
Bausch Health US, LLC5$69,038
Hoffmann-la Roche Limited7$59,072
Mylan Inc.18$55,932
Regeneron9$52,473
Biogen6$49,273
Biohaven Pharmaceutical Holding Company Ltd.19$46,684
Acadia Pharmaceuticals Inc5$35,039
Zogenix Inc.4$22,502
AMAG Pharmaceuticals, Inc.11$20,941
Roche TCRC, Inc.1$17,778
Chugai Pharmaceutical Co., Ltd.1$15,000
Gilead2$14,985
American Regent1$14,638
Incyte Corporation3$13,769
Biocryst Pharmaceuticals, Inc.1$11,500
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
Sanofi-aventis U.S. LLC5$5,663
Bavarian Nordic A/s1$1,900
Intuitive Surgical11$1,456
Atricure, Inc.2$592
Rhythm Pharmaceuticals, Inc.1$425
Shire North American Group Inc1$250
Boston Scientific1$37
Abbott1$25
Kls-martin L.p.1$17

How this compares

$50,456,531 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024
$1,932
Medicare patients
16
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in New Orleans

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →